1-20 of 44
Lihua E Budde
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Tamer Othman, Dongyun Yang, Sally Mokhtari, Ibrahim Aldoss, Geoffrey Shouse, Shukaib Arslan, Leonardo Farol, Leslie L. Popplewell, Ahmed Aribi, Alex F. Herrera, Lihua E. Budde, Joshua Mansour, Matthew Mei, Karamjeet S Sandhu, Tanya Siddiqi, Jasmine Zain, Vaibhav Agrawal, Idoroenyi Amanam, Vinod Pullarkat, Tycel J. Phillips, Ryotaro Nakamura, Stephen J. Forman, MHD Monzr M. Al Malki
Journal: Blood
Blood (2024) 144 (Supplement 1): 3534.
https://doi.org/10.1182/blood-2024-207125
Published: 2024
Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra, Timothy Voorhees, Madhav R Seshadri, Ayo S Falade, Alma Habib, Amy A. Ayers, Megumi Bailey, Annette Brown, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A. Jacobson, Joycelynne Michelle Palmer, Stephen J. Forman, Loretta Nastoupil, Lihua E. Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 524.
https://doi.org/10.1182/blood-2024-198749
Published: 2024
Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 3127.
https://doi.org/10.1182/blood-2024-198416
Published: 2024
Journal Articles

Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

Lihua E. Budde, Adam J. Olszewski, Bei Hu, Nikesh Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Kallemeijn, Victor Orellana-Noia, Lisa Musick, Natasha Shamas, Navdeep Pal, Ashwini Shewade, Jason R. Westin
Journal: Blood
Blood (2024) 144 (Supplement 1): 2373.
https://doi.org/10.1182/blood-2024-194340
Published: 2024
Journal Articles

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Tamer Othman, John H. Baird, Yan Wang, Stacy Pak, Ibrahim Aldoss, Ji-Lian Cai, Alexey Danilov, Tycel J. Phillips, Vaibhav Agrawal, Karamjeet S Sandhu, Matthew Mei, Paul B. Koller, Joycelynne Michelle Palmer, Stephen J. Forman, Lihua E. Budde, Ahmed Aribi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2278.
https://doi.org/10.1182/blood-2024-207085
Published: 2024
Journal Articles

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

James K. Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, Lucy Ghoda, Stephanie Vauleon, Alexey V. Danilov, Alex F. Herrera, Larry W. Kwak, Lihua E. Budde
Journal: Blood
Blood (2024) 144 (4): 457–461.
https://doi.org/10.1182/blood.2024024168
Published: 2024
Includes: Supplemental data
Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Tamer Othman, Christopher Ruel, Paul Frankel, Alexander A. Merleev, Guillaume Luxardi, Emanual Maverakis, Mehrdad Abedi, Raghuveer Ranganathan, Jasmine Zain, Lihua E Budde, Matthew Mei, Aaron S Rosenberg, Rasmus T Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Miguel Villalona-Calero, Elad Sharon, Joseph M Tuscano
Journal: Blood
Blood (2022) 140 (Supplement 1): 9446–9447.
https://doi.org/10.1182/blood-2022-167173
Published: 2022
Journal Articles

Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient

Ahmed Aribi, Lihua E Budde, Joseph C. Alvarnas, Eileen P. Smith, Amandeep Salhotra, Monzr M. Al Malki, Wen Yi-Ping, John Zaia, Guido Marcucci, Jana Dickter, Stephen J Forman
Journal: Blood
Blood (2022) 140 (Supplement 1): 7597–7598.
https://doi.org/10.1182/blood-2022-169223
Published: 2022
Journal Articles

Physical Therapy Assessment of Baseline Function and Endurance Predicts Short Term Outcomes in Commercial CAR T Patients with Lymphoma

Geoffrey Shouse, Rachel Tran, Jesse Osborn, Lihua E Budde
Journal: Blood
Blood (2021) 138 (Supplement 1): 570.
https://doi.org/10.1182/blood-2021-150858
Published: 2021
Journal Articles

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana A. Feldman, Jonathan E Brammer, Lu Chen, Leslie L. Popplewell, Lihua E Budde, Matthew Mei, Lori A. Leslie, Ranjit Nair, Chitra Hosing, Lacolle Peters, Stephen J Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P Iyer
Journal: Blood
Blood (2021) 138 (Supplement 1): 133.
https://doi.org/10.1182/blood-2021-151105
Published: 2021
Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136136
Published: 2020
Journal Articles

Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Geoffrey Shouse, DO, PhD, Thai Cao, MD, Jianying Zhang, Matthew Mei, MD, Alex F. Herrera, MD, Liana Nikolaenko, MD, Jasmine Zain, MD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD FACP, Stephen J. Forman, MD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-143353
Published: 2020
Journal Articles

Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program

Geoffrey Shouse, DO, PhD, Sylvia O Dulan, RN, Jamie Wagner, BS, Michelle Mott, RN, Alex Ly, Donna Ujiiye, Mary C. Clark, PhD, Kathie Viers, RN, Stephen J. Forman, MD, Eileen P. Smith, MD, David S Snyder, MD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10.
https://doi.org/10.1182/blood-2020-143412
Published: 2020
Journal Articles

Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience

Savita Dandapani, MD PhD, Geoffrey Shouse, DO, PhD, Jekwon Yeh, MD, Thai Cao, MD, Jeffrey Wong, MD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-143442
Published: 2020
Journal Articles

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Amandeep Salhotra, MD, Dat Ngo, PharmD, Jianying Zhang, Karamjeet S. Sandhu, MD, Monzr M. Al Malki, MD, Ahmed Aribi, MD, Haris Ali, MD, Pkoller Koller, MD, Shukaib Arslan, MD, Andrew S. Artz, MD, Lihua E Budde, MD PhD, Samer Khaled, MD, Sanjeet S Dadwal, MD, David S Snyder, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD, Anthony S. Stein, MD, Guido Marcucci, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-140538
Published: 2020
Journal Articles

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Michael Scordo, MD, Lihua E Budde, MD PhD, Mehrdad Abedi, MD, Carolyn Mulroney, MD, Bita Fakhri, MDMPH, Attaphol Pawarode, MDPhD, Bhagirathbhai Dholaria, MBBS, Edward Kavalerchik, MD, Sanjay K. Aggarwal, MD, Muzaffar H. Qazilbash, MD, Paul Finnegan, MD, Sergio A. Giralt, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-137257
Published: 2020
Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 759.
https://doi.org/10.1182/blood-2019-123163
Published: 2019
Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 760.
https://doi.org/10.1182/blood-2019-124254
Published: 2019
Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 6.
https://doi.org/10.1182/blood-2019-123742
Published: 2019
Journal Articles

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Anita Kumar, MD, Carla Casulo, Ranjana H Advani, MD, Lihua E Budde, MD PhD, Paul M. Barr, MD, Connie Lee Batlevi, MD PhD, Philip Caron, MD PhD, Louis S. Constine, MD, Savita Dandapani, MD PhD, Esther Drill, PhD, Pamela Drullinsky, MD, Jonathan W. Friedberg, MD, Clare Grieve, BA, Audrey Hamilton, MD, Paul A. Hamlin, MD, Richard T Hoppe, MD, Steven M. Horwitz, MD, Matthew J Matasar, MD, Susan Jennifer McCall, NP, Alison J. Moskowitz, MD, Ariela Noy, MD, Maria Lia Palomba, MD, Heiko Schoder, MD, David J. Straus, MD, Shreya Vemuri, Joanna C Yang, MD MPH, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 2834.
https://doi.org/10.1182/blood-2019-123150
Published: 2019